Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

Efficacy Study of a Selective Cytopheretic Device (SCD) in Patients With Acute Kidney Injury

Study:

A Multi-Center, Randomized, Controlled, Pivotal Study To Assess the Safety and Efficacy of A Selective Cytopheretic Device (SCD) In Patients With Acute Kidney Injury (AKI)

Rationale:

n/a

Purpose:

The purpose of this protocol is to evaluate the safety of a selective cytopheretic device (SCD) in patients that are on continuous renal replacement therapy (CRRT) for acute kidney injury (AKI).

Study Status: Recruiting

Recruiting:
Michelle Garcia 216-444-7753 GARCIAM1@ccf.org

Condition Intervention Phase
Acute Kidney Injury Device: SCD Phase 2

Verified by CytoPherx, Inc January, 2013

Sponsored by: CytoPherx, Inc
Information provided by: CytoPherx, Inc
ClinicalTrials.gov identifier: NCT01400893

Study Type: Interventional

Study Design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Cleveland Clinic
Cleveland, Ohio 44195
United States

n/a

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit ClinicalTrials.gov
  Information obtained from ClinicalTrials.gov on
Link to the current ClinicalTrials.gov record.

Cleveland Clinic Mobile Site